For the 22nd prioritisation (April 2015), 10 were filtered out of 180 identified drugs and were sent to prioritisation. Of these, 4 drugs were ranked as "highly relevant" by the expert panel, 4 as "relevant" and 2 as "not relevant". For "highly relevant" drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.